2025年,由于两个主要客户的销售量减少,综合生物药厂的收入在问题3下下降了6.6%。 Integrated BioPharma's revenue fell 6.6% in Q3 2025 due to lower sales from two major customers.

综合生物制药公司报告说,2025年9月30日结束的季度收入为1 270万美元,比去年同期的1 360万美元减少6.6%。 Integrated BioPharma reported $12.7 million in revenue for the quarter ended September 30, 2025, a 6.6% decrease from $13.6 million in the same period last year. 业务收入从50万美元降至20万美元,净收入降至10万美元,即每股0.00美元,而上一年季度为30万美元,即每股0.1美元。 Operating income dropped to $0.2 million from $0.5 million, and net income fell to $0.1 million, or $0.00 per share, compared to $0.3 million, or $0.01 per share, in the prior-year quarter. 该公司将收入下降归因于合同制造部门两个最大客户的收入减少,这两个部门分别占总收入的87%和85%。 The company attributed the decline to reduced revenue from its two largest customers in the Contract Manufacturing Segment, which accounted for 87% and 85% of total revenue in the respective quarters. 该公司在维生素、营养补充剂和草药产品部门开展业务。 The company operates in the vitamins, nutritional supplements, and herbal products sector. 前瞻性声明包括与市场条件、竞争、监管和供应链依赖性有关的风险。 Forward-looking statements include risks related to market conditions, competition, regulation, and supply chain dependencies.